Movement Disorders

Insights about where stem cell treatment of neurological diseases is headed.

New early-stage data suggest that vector‐mediated gene silencing of striatal CaV1.3 expression may hold promise for preventing the induction of levodopa-induced dyskinesias in Parkinson disease.

The FDA has expanded the indication for incobotulinumtoxinA, making it a first-line treatment for blepharospasm.

The chief medical officer of Neurocrine Biosciences spoke about how long-term data on valbenazine (Ingrezza) has helped shape the understanding of the effect tardive dyskinesia can have on patients, and how it can inform better utilization of the medication.

Although the primary end point of centrally video-rated TETRAS Performance Subscale did not achieve statistical significance, CX-8998-treated patients showed significant improvements in a number of other measurements.

The guideline, which is endorsed by the Child Neurology Society and the European Academy of Neurology, is the first guideline on the topic for US-based clinicians.

Although animal models and early phase studies suggested some potential for the hypertension medication to slow disability progression in Parkinson disease, a phase 3 assessment showed a lack of treatment effect.

The proprietary software utilizes sophisticated algorithms and 7T MRI data to predict the location of the subthalamic nuclei, a key target for deep brain stimulation for the treatment of Parkinson disease.

NuPlasma yFFP was associated with improvements in complications of therapy, motor examination scores, mentation, behavior, and mood, and in activities of daily living in patients with Parkinson disease.

Responses from 1300 physicians suggest that increasing patient load and adding ancillary services may be the key to increasing annual income.

Neurology News Network for the week of April 20, 2019.

It has been estimated that between 40% and 60% of patients with PD use at least one form of complementary medicine. In this podcast, neurologist Sarah Mulukutla, MD, MPH talks about CAM options for neurologists to discuss with their patients.

In an ongoing phase 2 study, 21 nonambulatory participants with Duchenne muscular dystrophy passed the 52-week treatment mark.

Neurology News Network for the week of April 13, 2019.

The chief scientific officer of the Parkinson’s Foundation spoke about the developing interest in genetic forms of Parkinson, the potential to target therapies in that direction, and how a genetic treatment is the next big stage for the field.

The chief scientific officer at the Parkinson's Foundation spoke about the need to increase awareness about the proper care of patients with Parkinson disease.

According to Kyowa Kirin, the investigational selective adenosine A 2A receptor antagonist has had its PDUFA action date set for August 27, 2019.

A study looked at at levodopa/carbidopa administration soon after the diagnosis of Parkinson disease.

Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.

Neurology News Network for the week of March 30, 2019.

The Movement Disorder Society Task Force on Technology has released a roadmap for the implementation of new technologies that have reached a level of sophistication, versatility, and wearability for Parkinson disease.

Neurology News Network for the week of March 22, 2019.

An analysis of the EARLYSTIM study data has suggested that the 39-item Parkinson’s Disease Questionnaire summary index may be predictive of the future outcomes of subthalamic deep brain stimulation.

Ned Sharpless, MD, the director of the National Cancer Institute, has been named to the position of acting FDA Commissioner. The announcement was made just a week after the current commissioner, Scott Gottlieb, MD, announced his plans to resign in early April.

Neurology News Network for the week of March 9, 2019.